#### Curriculum Vitae

## Joyce E. Davidson, MD

# I. General Biographical Information

#### A. Personal

- a. Name—Joyce E. Davidson, MD
- b. Date of Birth-November 12, 1954
- c. Citizenship--USA

### B. Education

- a. Undergraduate Education—University of Missouri—Kansas City, B.A. in Biology 1978
- b. Medical Education—University of Missouri—Kansas City School of Medicine, MD degree 1979
- c. Postgraduate Training—1979-1983—General Psychiatry Residency, Karl Menninger School of Psychiatry, Topeka, Kansas., 1982-1984— Child Psychiatry Fellowship, Karl Menninger School of Psychiatry, Topeka, Kansas.

# C. Academic Appointments

- a. 2001 to present—Assistant Professor of Psychiatry, Baylor College of Medicine
- b. 1984 to 2001—Faculty, Karl Menninger School of Psychiatry

#### D. Other Advanced Training

a. Cognitive Therapy Training, Kansas City Center for Cognitive Therapy, 1993-1999

### E. Other Information

- a. Honors and Awards—Merck Award—1979; E.E. Southard Award for Medical Writing, 1984; Arnold Block Professorship, 1985
- b. Board Certification/Eligibility—Certified by the American Board of Psychiatry and Neurology, 1988; Board Eligible in Child and Adolescent Psychiatry.
- c. Other non-academic positions—Board Member, Houston Area Mental Health Association

### II. Research Information

#### A. Research Support

a. Co-principal investigator, A Prospective, Randomized, Double-blind, Placebo- and Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Iloperidone 4,8, and 12mg/d) given b. i. d. for 42 days to Schizophrenic Patients with Acute or Subacute

Exacerbation, Followed by a Double-blind, Active-controlled, Flexible-Dose Long Term, 6-month Phase with Iloperidone (4, 8, 12, and 16mg/d) given q.d., Novartis Pharmaceuticals Corporation, 1998-1999.

b. Sub-investigator, Phase II, Six-week, Double-blind, Placebo- and Olanzapine-controlled Study Evaluating the Safety and Efficacy or Oral CP-361,428 in Schizophrenic Disorder, Pfizer #245-102-5017

c. Co-principal Investigator, Hoechst Marion Roussel, Inc. Protocol 100907PR0018, A Multicenter, Open-Label, Long-Term Followup, Safety Study of MDL100,907 in Schizophrenic and Schizoaffective Patients who participate in the Study 100907PR0015, 1997-1998.

d. Co-Principal Investigator, Hoechst Marion Roussel, Inc. Protocol 100907PR0015, a Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of MDL100,907 in Schizophrenic and Schizoaffective Patients, 1997-1998.

e. Co-principal Investigator, Janssen, Protocol RIS-USA-68-01, A Bioequivalence Study Comparing an 8-mg Risperidone Tablet With Two 4-mg Risperidone Tablets in Chronic Schizophrenic Patients, 1995-1996.

f. Principal Investigator for Compassionate Use of Clozapine Study, 1988-1990. This project afforded me the opportunity to make clozapine available to patients at Menninger and the Topeka community two years prior to its general release.

B. National Scientific Participation

a. Editorial Board—Bulletin of the Menninger Clinic, 2000-2004.

b. Professional Societies—Member, American College of Psychiatrists Invited lectures and presentations—

#### C. Publications:

a. Full Papers with peer review:

- 1. Davidson., J., Allen, J., and Smith, W. H. (1987). Complexities in the hospital treatment of the multiple personality patient. Bulletin of the Menninger Clinic, 51(6), 561-568.
- 2. Davidson, J. (1988). Psychiatric aspects of HIV infection. Kansas Medicine, 89(4),
- 3. Gabbard, G., Takahashi, T., Davidson, J., Bauman-Bork, M., and Ensroth, K. (1991). A psychodynamic perspective on the clinical impact of insurance review. <u>American Journal</u> Psychiatry, 148, 318-323.

4. Davidson, J., Bjorgvinsson, T. (2003) Current and potential pharmacological treatments for obsessive –compulsive disorder. Expert Opin. Investig. Drugs 12 (3) 993-1001.

# b. Other full papers:

1. Davidson, J. (1988) Psychiatric aspects of HIV infection. Kansas Medicine 89 (4)

## III. Teaching Information

- A. Didactic course work:
  - a. Courses taught at BCM—Cognitive-behavioral therapy, 12 hours yearly
- B. Non-didactic teaching at BCM
  - a. Resident training—5 hours/week
- C. Lectures—

1986, 1988, 1989, 1990 "Physicians and Their Families," faculty member, Estes Park, CO

"Psychosocial Aspects of Oncology," faculty member

"Time-Limited Psychotherapy" University of Kansas School of Medicine, Wichita, Kansas, April 9, 1999

"Cognitive Therapy with Schizophrenia" The Menninger Clinic, Topeka, Kansas, September 29, 2000

"Animal Cruelty and Psychopathology" Humane Society Topeka, Kansas, December, 2000

"Treatment of Complicated Anxiety Disorders in Adolescents and Adults" Baylor Psychopharmacology Conference October, 7, 2001

"Intensive CBT for Hypochondriasis" Obsessive-Compulsive Foundation, Philadelphia, PA, August 9, 2002

## IV. Medical and Service Information

- a. Patient care responsibilities—
  - 1. Medical Director, OCD Treatment Program, The Menninger Clinic
  - 2. Staff Psychiatrist, Baylor Psychiatry Clinic
- b. Administrative assignments at BCM
  - 1. Psychiatry Department Committees: Admissions and Progressions Committee
- c. Other—Permitted wildlife rehabilitator, Gulf Coast Wildlife Rescue